derm downgrad neutral pend
acquisit
messag expect acquisit derm final
announc price result downgrad derm
neutral buy consist expect close fair valu estim
derm expect new bidder emerg although
price look like bargain given compani overal immunolog portfolio
includ olumi baricitinib jak inhibitor rheumatoid arthriti taltz anti
psoriasi potenti mirikizumab anti psoriasi uc crohn diseas
neutral rate derm
qbrexza trx remain flat decreas overal profit revenu cost
go decreas revenu qbrexza peak sale potenti
time decreas cost relat promot
product estim peak sale lebrikizumab moder sever
atop dermat pay royalti sale roch
rog-swx eu lebrikizumab sale book almiral alm mc
derm get royalti lebrikizumab current evalu phase
result expect compani earli lebrikizumab show impress result
low rate conjunct differenti itch phase see note lebrikizumab
impact itch safeti differenti massiv atop dermat market
believ give stiff competit san-par/regn dupix potenti massiv
atop dermat market global estim
despit bullish view lebrikizumab robust sale process execut
expect new bidder emerg break-up fee derm/lli transact
standard low singl digit percentag transact valu howev
potenti acquir contact avail robust process execut
expect late bidder emerg
figur qbrexza trx actual forecast actual
page analyst certif import disclosur
figur forecast sale qbrexza
guggenheim estim sale qbrexza
valuat risk
npv-base fair valu rang base forecast sale profit
discount rate consist discount rate
compani earli commerci de-risk asset
upsid risk better expect result lebrikizumab phase trial
potenti anoth bidder derm valu reviv growth trend
qbrexza along increas profit
downsid risk lebrikizumab failur phase trial slower
expect uptak qbrexza convert debt due may
page analyst certif import disclosur
lebrikizumab revenu dermira
lebrikizumab royalti almiral eu sale
collabor licens revenu
total servic
cog sale
gross margin product sold
revenu
revenu
discountinu op net tax
total servic
compani report guggenheim secur llc estim
page analyst certif import disclosur
